secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-040183
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm grants annual equity awards to CEO Paulson and CFO Mason under 2022 Plan
--------------------------------------------------------------------------------

- CEO Richard Paulson receives 252,000 time-based RSUs and 252,000 target PSUs (0-200% vesting).
- CFO Michael Mason receives 95,000 time-based RSUs and 80,000 target PSUs.
- PSU vesting tied 33% each to: 3-year revenue, 3 clinical milestones, and relative TSR vs Nasdaq Biotech Index.
- Clinical milestone PSUs have a 1-year minimum vesting; performance measured over 3-year periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/0001193125-23-040183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/d459493d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-040183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer